ATAI LIFE SCIENCES BV EO1 (F:9VC) — Market Cap & Net Worth
Market Cap & Net Worth: ATAI LIFE SCIENCES BV EO1 (9VC)
ATAI LIFE SCIENCES BV EO1 (F:9VC) has a market capitalization of $1.29 Billion (€1.10 Billion) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #8022 globally and #1062 in its home market, demonstrating a 4.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ATAI LIFE SCIENCES BV EO1's stock price €3.55 by its total outstanding shares 363214602 (363.21 Million).
ATAI LIFE SCIENCES BV EO1 Market Cap History: 2021 to 2026
ATAI LIFE SCIENCES BV EO1's market capitalization history from 2021 to 2026. Data shows change from $2.79 Billion to $1.51 Billion (-27.74% CAGR).
ATAI LIFE SCIENCES BV EO1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ATAI LIFE SCIENCES BV EO1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9VC by Market Capitalization
Companies near ATAI LIFE SCIENCES BV EO1 in the global market cap rankings as of May 4, 2026.
Key companies related to ATAI LIFE SCIENCES BV EO1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ATAI LIFE SCIENCES BV EO1 Historical Marketcap From 2021 to 2026
Between 2021 and today, ATAI LIFE SCIENCES BV EO1's market cap moved from $2.79 Billion to $ 1.51 Billion, with a yearly change of -27.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.51 Billion | +5.54% |
| 2025 | €1.43 Billion | +178.99% |
| 2024 | €511.26 Million | -11.50% |
| 2023 | €577.72 Million | -42.62% |
| 2022 | €1.01 Billion | -63.86% |
| 2021 | €2.79 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of ATAI LIFE SCIENCES BV EO1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.29 Billion USD |
| MoneyControl | $1.29 Billion USD |
| MarketWatch | $1.29 Billion USD |
| marketcap.company | $1.29 Billion USD |
| Reuters | $1.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ATAI LIFE SCIENCES BV EO1
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more